赛诺菲四价流感疫苗恢复在华销售

Core Viewpoint - Sanofi China has received approval from the National Medical Products Administration for its quadrivalent influenza virus split vaccine for the 2025-2026 flu season [1] Company Summary - Sanofi China announced the approval of its quadrivalent influenza vaccine, indicating a significant step in its product offerings for upcoming flu seasons [1]